Fatty-acid trafficking in cells is a complex and dynamic process that affects many aspects of cellular function. Fatty acids function both as an energy source and as signals for metabolic regulation, acting through enzymatic and transcriptional networks to modulate gene expression, growth and survival pathways, and inflammatory and metabolic responses 1,2 . Furthermore, fatty acids, particularly linoleic and arachidonic acids, can be metabolized into a diverse and large family of bioactive lipid mediators called eicosanoids, which may function as pro-and anti-inflammatory mediators 3, 4 . In particular, the cyclopentenone prostaglandins, such as PGA1, PGA2 and PGJ2, have potent anti-inflammatory effects through the inhibition of inflammatory kinase pathways. A critical regulatory component of eicosanoid biosynthesis is at the level of availability of unesterified fatty acids liberated from membrane phospholipids. All of these aspects depend on complex processing, shuttling, availability and removal of lipids to keep a delicate balance between lipid species at the target compartments and to regulate their engagement of signalling targets.
. In particular, the cyclopentenone prostaglandins, such as PGA1, PGA2 and PGJ2, have potent anti-inflammatory effects through the inhibition of inflammatory kinase pathways. A critical regulatory component of eicosanoid biosynthesis is at the level of availability of unesterified fatty acids liberated from membrane phospholipids. All of these aspects depend on complex processing, shuttling, availability and removal of lipids to keep a delicate balance between lipid species at the target compartments and to regulate their engagement of signalling targets.
Intracellular lipid chaperones known as fatty acidbinding proteins (FABPs) are a group of molecules that coordinate lipid responses in cells and are also strongly linked to metabolic and inflammatory pathways [5] [6] [7] [8] [9] . FABPs are abundantly expressed 14-15 kDa proteins that reversibly bind hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids, eicosanoids and other lipids, with high affinity 8, 9 . FABPs are found across species, from Drosophila melanogaster and Caenorhabditis elegans to mice and humans, demonstrating strong evolutionary conservation. However, little is known about their exact biological functions and mechanisms of action. Studies in cultured cells have suggested potential action of FABPs in fatty-acid import, storage and export as well as cholesterol and phospholipid metabolism 5, 6 . FABPs have also been proposed to sequester and/or distribute ligands to regulate signalling processes and enzyme activities. In the broader context, we view FABPs as lipid chaperones that escort lipids and dictate their biological functions. Recently, through the use of various genetic and chemical models in cells as well as whole animals, the FABPs have been shown to be central to lipid-mediated processes and related metabolic and immune response pathways. Such studies have also highlighted their considerable potential as therapeutic targets for a range of associated disorders, including obesity, diabetes and atherosclerosis.
Family of FABPs
Since the initial discovery of FABPs in 1972 (REF. 10 ), at least nine members have been identified (TABLE 1) . Different members of the FABP family exhibit unique patterns of tissue expression and are expressed most abundantly in tissues involved in active lipid metabolism. The family contains liver (L-), intestinal (I-), heart (H-), adipocyte (A-), epidermal (e-), ileal (Il-), brain (B-), myelin (m-) and testis (T-) FABPs. However, it should be noted that this classification is somewhat misleading, as no FABP is exclusively specific for a given tissue or cell type, and most tissues express several FABP isoforms (see below). The regulation of tissue-specific expression and function of various FABPs is poorly understood. The expression of FABPs in a given cell type seems to reflect its lipid-metabolizing capacity. In hepatocytes, adipocytes and cardiac myocytes, where fatty acids are prominent substrates for lipid biosynthesis, storage or breakdown, the respective FABPs make up between 1% and 5% of all soluble cytosolic proteins 5 . These amounts can further increase following periods of mass influx of lipids into these cells. Increased fatty-acid exposure leads to a marked increase in FABP expression in most cell types 11 . endurance training or pathological nutrient changes, as seen in diabetes for example, can also result in high levels of FABP in skeletal muscle cells 12 . Similar effects have also been seen in hepatocytes and adipocytes after exposure to chronically elevated extracellular lipid levels 11 . These observations suggest that there is a built-in adaptive sensing system that responds to the lipid status of the target cells and regulates lipid stochiometry with the FABPs.
As small intracellular proteins, FABPs appear to access the nucleus under certain conditions, and potentially target fatty acids to transcription factors, such as members of the peroxisome proliferator-activated receptor (PPAR) family -PPAR-α, PPAR-δ and PPAR-γ -in the nuclear lumen. L-FABP, H-FABP, A-FABP and e-FABP themselves are controlled by these transcription factors, which are liganded by fatty acids or other hydrophobic agonists [13] [14] [15] . L-FABP and PPAR-α physically interact, and therefore it has been suggested that L-FABP could be considered a co-activator in PPAR-mediated gene regulation 16 . In a similar way, e-FABP interacts with PPAR-δ and A-FABP with PPAR-γ 15 . A recent study has indicated that continuous nucleocytoplasmic shuttling may underlie transcriptional activation of PPAR-γ by A-FABP 17 . However, in the case of A-FABP, its actions also provided a negative feedback to terminate PPAR-γ action, and the absence of A-FABP resulted in enhanced nuclear hormone receptor activity in the macrophage 18 . It is unclear whether such a feedback regulation occurs with other isoforms in other cell types and how specificity is achieved in the chaperoning activity towards lipid species.
Ligand affinity and structure of FABPs All FABPs bind long-chain fatty acids with differences in ligand selectivity, binding affinity and binding mechanism 6 as a result of small structural differences between isoforms. In general, the more hydrophobic the ligand the tighter the binding affinity -with the exception of unsaturated fatty acids. It is also possible that the needs of target cells determine the affinity and even selectivity of the major isoform present at different sites. For example, B-FABP is highly selective for very long-chain fatty acids such as docosahexaenoic acid 19 . on the other hand, L-FABP exhibits binding capacity for a broad range of ligands from lysophospholipids to haem 8 . Several FABP isoforms have been structurally investigated as isolated recombinant proteins by X-ray crystallography, nuclear magnetic resonance and other biochemical and biophysical techniques. FABPs have an extremely wide range of sequence diversity: from 15% to 70% sequence identity between different members 6 . However, all known FABPs share almost identical threedimensional structures
. Common to all FABPs is a 10-stranded antiparallel β-barrel structure, which is formed by two orthogonal five-stranded β-sheets 6 . The binding pocket is located inside the β-barrel, the opening of which is framed on one side by the n-terminal helix-loop-helix 'cap' domain, and fatty acids are bound to the interior cavity. There is a conserved three-element fingerprint that provides a signature for all FABPs (PRInTS pattern FATTYACIDBP; PR00178)
Functions of FABPs numerous functions have been proposed for FABPs. As lipid chaperones, FABPs may actively facilitate the transport of lipids to specific compartments in the cell, such as to the lipid droplet for storage; to the endoplasmic reticulum for signalling, trafficking and membrane synthesis; to the mitochondria or peroxisome for oxidation; to cytosolic or other enzymes to regulate their activity; to the nucleus for lipid-mediated transcriptional regulation; or even outside the cell to signal in an autocrine or paracrine manner (FIG.1) . The proper engagement of targets in a spatially controlled manner requires the action of lipid chaperones. Interestingly, the functions of lipid chaperones studied so far relate to detrimental outcomes.
FABP content in most cells is generally proportional to the rates of fatty-acid metabolism 11 . FABPs are also involved in the conversion of fatty acids to eicosanoid intermediates and in the stabilization of leukotrienes 20, 21 . Furthermore, a direct protein-protein interaction between hormone-sensitive lipase (HSL) activity and A-FABP or e-FABP in adipocytes has also been reported [22] [23] [24] [25] . In general, the interacting protein partners for FABPs are poorly understood, and the searches for such proteins with conventional approaches have not been fruitful. movement of FABPs into the nucleus and interaction with nuclear hormone receptors is possible, and this mechanism might potentially deliver ligands to this protein family [15] [16] [17] 26 . Again, little is known regarding this potential action and how lipids regulate subcellular localization of FABPs. Also, how these simple chaperones overcome specificity or stoichiometry constraints remains elusive. Clear evidence on the specific impact of FABPs on cell biology and lipid metabolism in complex systems had been lacking until FABP-deficient mice models were created. As discussed below, consequences of genetically altered FABP expression in cells or whole animals dramatically enhanced the understanding of FABP functions (TABLEs 2,3), but also raised interesting new questions and possibilities regarding systemic effects of FABPs in vivo and the underlying mechanisms. These studies also opened up novel possibilities to tackle a wide range of metabolic diseases through therapeutic targeting of FABPs, particularly A-FABP, with synthetic ligands.
Liver FABP. L-FABP, also known as FABP1, is abundant in the liver cytoplasm, but is also expressed in several other sites, including the intestine, pancreas, kidney, lung and stomach 6 . L-FABP in the liver can represent as much as 5% of all cytosolic proteins in hepatocytes 5 . The promoter of the L-FABP gene contains a peroxisome-proliferator response element, and accordingly the mRnA levels are increased by fatty acids, dicarboxylic acids and retinoic acid 8 . unlike the other members of the FABP family, L-FABP is able to bind two ligands simultaneously via two different binding sites with high and low affinities 27 . Peroxisome proliferators always bind L-FABP with low affinity, whereas the strength of the binding with fatty acids depends on which affinity site is utilized. This property of L-FABP is suggested to serve as a feature enabling ligand delivery through interactions with target receptors. In addition to binding fatty acids, such as oleic acid, L-FABP can carry acyl-coenzyme A, eicosanoids, lysophospholipids, carcinogens, anticoagulants, such as warfarin, and haem, making it probably the most versatile chaperone in terms of its ligand repertoire 8 . Surprisingly, no change in appearance, gross morphology or viability was observed in L-FABP-deficient mice 28, 29 . These mice were of normal weight, and despite a modest reduction in fatty-acid uptake, serum levels of triacylglycerols and fatty acids were unchanged 28, 29 . However, metabolic parameters in mice upon exposure to high-fat/cholesterol diet differed between studies [30] [31] [32] (TABLE 2). This fragility in the phenotype points to the critical importance of the dietary exposures, gender and subtle differences in genetic background or lipid composition in the biology of L-FABP. It is also possible that the principal action of L-FABP lies elsewhere, for example in the kidney or intestine. Interestingly, recent studies have suggested that fatty acid-induced expression of L-FABP occurs in the proximal tubules and showed that urinary L-FABP in humans may be a useful clinical marker that can help predict and monitor the progression of renal diseases 33 .
Intestinal FABP. I-FABP, also known as FABP2, is expressed in the epithelium of the small intestine. In the small intestine, three members of FABPs are present, namely L-FABP, I-FABP and Il-FABP (also known as FABP6), although they are distributed in different segments 34 . L-FABP is mostly expressed in the proximal region, whereas Il-FABP is restricted to the distal part of the small intestine. I-FABP is expressed throughout the intestine, but most abundantly in the distal segment. It is difficult to assess the individual contributions of these proteins to lipid absorption and metabolism at the sites at which they are present, and more work is needed in this regard.
I-FABP-deficient mice were viable and fertile 35 . Fat absorption was not affected by the loss of I-FABP, and compensation by L-FABP or Il-FABP was not observed 35 . Both genders of mice with I-FABP-deficiency exhibited elevated plasma levels of insulin, but normal levels of glucose. male I-FABP -/-mice gained more weight, had larger livers and had significantly higher triglyceride levels regardless of diet. By contrast, female I-FABP diet and exhibited no difference in plasma triglyceride levels. Although the mechanisms responsible for these gender differences remain unclear, it appears that fattyacid uptake can be mediated by the remaining FABPs, possibly L-FABP and Il-FABP, without the need for increased total amounts of FABPs to compensate for the lack of I-FABP. It has been reported that a polymorphism in I-FABP, an alanine to threonine substitution at codon 54 (Thr54), was associated with insulin resistance and decreased lipid oxidation in Pima Indians, a population with an extremely high prevalence of obesity and type 2 diabetes 36 . However, the association between the Thr54 allele and insulin resistance in various other populations has been modest and sometimes controversial 5, 6 . Again, this indicates the need to examine these genetic variations in large populations, and, more importantly, in the context of dietary and other environmental exposures.
Heart FABP. H-FABP, also known as FABP3, has been isolated from a wide range of tissues, including heart, skeletal muscle, brain, renal cortex, lung, testis, aorta, adrenal gland, mammary gland, placenta, ovary and brown adipose tissue 6, 12 . The level of H-FABP was influenced by exercise, PPAR-α agonists and testosterone, and oscillates with circadian rhythm 8, 14, 37 . In muscle cells, H-FABP was involved in the uptake of fatty acids and their subsequent transport towards the mitochondrial β-oxidation system. Increased fatty-acid exposure in vitro and in vivo resulted in elevated H-FABP expression 11, 12 . Conditions with elevated plasma lipids may result in increased H-FABP levels in myocytes, as seen in endurance training 11, 12 .
Studies in H-FABP-deficient mice showed that the uptake of fatty acids was severely inhibited in the heart and skeletal muscle, whereas plasma concentrations of free fatty acids were increased 38 . Cardiac and skeletal muscle metabolism is reported to switch from fatty-acid oxidation towards glucose oxidation when there is an inability to obtain sufficient amounts of fatty acids 39, 40 . Consequently, H-FABP-deficient mice were rapidly fatigued and exhausted by exercise, showing a reduced tolerance to physical activity. Localized cardiac hypertrophy was also observed in the older animals 38 . The mammary gland prominently expresses H-FABP in the course of cell differentiation and formation of ductal structures during lactation 41 . In the mammary gland, mammary-derived growth inhibitor (mDGI) was identified as a growth regulator, which later turned out to be a mixture of H-FABP and A-FABP, and the amino-acid sequence of mDGI reveals 95% similarity to H-FABP 42, 43 . It has been shown that H-FABP inhibits the growth of human breast cancer cells 44 . However, this growth inhibition appeared to be unrelated to the ligand-binding capacity of the FABPs. on the other hand, studies involving overexpression and ablation of H-FABP demonstrated that H-FABP did not play a role in regulating the development or function of the mammary gland 45, 46 . Thus, the biological function of H-FABP in the mammary gland remains unclear and somewhat controversial. Similarly, little is known about the effect of lack of H-FABP in tissues other than the heart or mammary gland.
H-FABP is abundant in the myocardium and rapidly released from cardiomyocytes into the circulation after the onset of cell damage. Serum concentration of H-FABP has been proposed as an early biochemical marker of acute myocardial infarction and a sensitive marker for the detection and evaluation of myocardial damage in patients with heart failure 47, 48 . However, the concentration of H-FABP is significantly influenced by
Box 1 | Crystal structure of ligand-bound FABPs
Generally, one or two conserved basic amino-acid side chains are required to bind the carboxylate site of a fatty-acid ligand in the binding pocket of a fatty acid-binding protein (FABP) 6, 9 . The hydrocarbon tail of the ligand is lined on one side by hydrophobic amino-acid residues and on the other side by ordered water molecules, thus creating the small differences of FABP types in the enthalpic and entropic contributions to ligand binding. Below, the crystal structures of various ligand-bound FABPs are shown (graphics were created using PyMOL).
The binding pocket of liver FABP (L-FABP; FABP1) is considerably larger than that of other FABPs, allowing the binding of two fatty-acid molecules with differing affinities (a). Here, two oleic acids are bound to rat L-FABP (Protein Data Bank (PDB) code: 1lfo), and show that the fatty acids are bound in opposite orientation with the carboxylate group of the second fatty acid protruding from the cavity and facing the solvent 96 . In rat intestinal FABP (I-FABP; FABP2), the ligand (palmitic acid) is bound in a slightly bent conformation 97 (PDB code: 2ifb) (b). Other members generally bind a fatty acid as a twisted U-shaped entity 9, 98 : a palmitic acid bound to human heart FABP (H-FABP; FABP3) (PDB code: 2hmb) (c); a palmitic acid bound to human adipocyte FABP (A-FABP; FABP4) (PDB code: 2hnx) (d); a palmitic acid bound to human epidermal FABP (E-FABP; FABP5) (PDB code: 1b56) (e); an oleic acid bound to bovine myelin FABP (M-FABP; FABP8) (PDB code: 1pmp) (f). An exception is for human ileal FABP (Il-FABP; FABP6), which binds the bile acid such as taurocholic acid (PDB code: 1o1v) (g). Human brain FABP (B-FABP; FABP7) binds oleic acid in the U-shaped way (PDB code: 1fe3) (h); however, its binding pocket can also accommodate very long-chain docosahexaenoic acid in a helical conformation 19 (PDB code: 1fdq) (i).
A-FABP (FABP4): 
Box 2 | Domain distribution of FABP family members
There is a conserved fingerprint for all fatty acid-binding proteins (FABPs) (PRINTS pattern FATTYACIDBP; PR00178), which is derived from three motifs. Motif 1 includes the G-x-W triplet, which forms part of the first β-strand (βA) and corresponds to a similar motif in the sequence of lipocalins, in which it has the same conformation and location within the protein fold 99 (see PROSITE pattern FABP; PS00214). Motif 2 spans the C terminus of strand 4 (βD) and includes strand 5 (βE). Motif 3 encodes strands 9 (βI) and 10 (βJ).
In adipocyte FABP (A-FABP; FABP4), potential functional domains include a nuclear localization signal (NLS) and its regulation site, nuclear export signal (NES) and a hormone-sensitive lipase (HSL) binding site 17, 26, 100 . The primary sequence of A-FABP does not show a readily identifiable NLS. However, the signal could be found in the 3D structure of the protein and was mapped to three basic residues (K21, R30 and K31) located in the helix-loop-helix region, whose side chains shift their orientation upon ligand binding to form a functional NLS 17 . The NES is also not apparent in the primary sequence, but assembles in the tertiary structure from three nonadjacent leucine residues (L66, L86 and L91) to form a motif reminiscent to that of established NES 17 . Activation of NLS in A-FABP involves closure of the portal loop, resulting in contraction of the binding pocket. Swinging doorway comprised of F57 perturbs a critical helix containing the NLS 26 . It has been suggested that activated and non-activated ligand conformations of A-FABP for NLS have different homodimeric configurations. Non-activating ligands (for example, oleate and stearate) protrude from the portal, preventing its closure and preserving the integrity of a homodimeric interface, which masks the NLS, while activating ligands (for example, troglitazone, linoleic acid and anilinonaphthalene sulphonate) favour an alternative homodimer in which the NLS is exposed 26 . The representative crystal structure of FABP is human A-FABP (PDB code: 2hnx). The structural and functional domains as well as critical amino-acid residues are marked. The graphic depiction of protein structure was created with PyMOL. Nature Reviews | Drug Discovery . The utility of these potential biomarkers remains to be explored.
Adipocyte FABP. A-FABP, also known as FABP4, was first detected in mature adipocytes and adipose tissue 51, 52 . This protein has also been termed adipocyte P2 (aP2) because of its high sequence similarity (67%) to peripheral myelin protein 2 (m-FABP/FABP8) 52 . expression of A-FABP is highly regulated during differentiation of adipocytes, and its mRnA is transcriptionally controlled by fatty acids, PPAR-γ agonists and insulin 5, 7 . A-FABP is the best-characterized isoform among the entire FABP family with the most striking biology (FIG. 2) . A-FABP-deficient mice exhibited reduced hyperinsulinaemia and insulin resistance in the context of both dietary and genetic obesity, but the effect of A-FABP on insulin sensitivity was not observed in lean mice 53, 54 . In adipocytes, the loss of A-FABP was compensated by overexpression of e-FABP (FABP5/mal1), which is present in the normal adipocyte only in extremely small amounts. The adipocytes obtained from A-FABPdeficient mice have reduced efficiency of lipolysis in vitro and in vivo [22] [23] [24] . This was initially attributed to the ability of A-FABP to bind and activate HSL, although the definitive links between HSL activation and A-FABP have not yet been established in vivo. It also remains to be seen whether this potential mechanism can account for the alterations in lipolysis in A-FABP-deficiency.
Recent studies have demonstrated A-FABP expression in macrophages upon their differentiation from monocytes, and following activation with phorbol 12-myristate 13-acetate, lipopolysaccharide, PPAR-γ agonists and oxidized low-density lipoprotein [55] [56] [57] [58] [59] . In addition, it has been reported that A-FABP is also expressed in the dendritic cells 60 . Interestingly, expression of A-FABP in macrophages was suppressed by a cholesterol-lowering statin in vitro 61 . notably, adipocytes express much higher levels of A-FABP than macrophages (approximately 10,000-fold) 62 . In macrophages, A-FABP modulated inflammatory responses and cholesterol ester accumulation 55 , and total A-FABP deficiency conferred dramatic protection against atherosclerosis in apolipoprotein e (ApoE)-deficient mice with or without the additional challenge of high-cholesterol-contained western diets 55, 63 . Bonemarrow transplantation studies demonstrated that this atheroprotective effect of A-FABP is predominantly, if not entirely, related to its actions in the macrophage 55 . These results demonstrate a central role for A-FABP in the development of major components of the metabolic syndrome through its distinct actions in adipocytes and macrophages, and its ability to integrate metabolic and inflammatory responses.
In human and mouse monocyte cell lines, A-FABP expression became evident in differentiated or activated macrophages [55] [56] [57] [58] [59] . The 5.4 kilobase A-FABP promoter/enhancer, which is known to direct A-FABP expression in the adipocytes, was sufficient to induce the expression in macrophages as tested in three independent transgenic lines 55 . Interestingly, e-FABP was also present in macrophages and regulated in an essentially identical manner. unlike the compensatory regulation in adipocytes, e-FABP did not appear to be significantly upregulated in macrophages derived from A-FABP -/-mice (termed A-FABP -/-macrophages) 55 . It has been suggested that A-FABP is a critical regulator of the PPAR-γ-liver X receptor-α (LXR-α)-ATP-binding cassette A1 (ABCA1) pathway and contributes to foam-cell formation in macrophages 18 . PPAR-γ activity was elevated in A-FABP -/-macrophages with stimulation of downstream targets including LXR-α and ABCA1, resulting in enhanced efflux of cholesterol 18 . In parallel, A-FABP coordinates the inflammatory activity of macrophages. In A-FABP -/-macrophages, several inflammatory signalling responses were suppressed, including production of cytokines such as tumour-necrosis factor-α (TnF-α), interleukin 1β (IL1β), IL6 and monocyte chemoattractant protein 1 (mCP1). moreover, production and function of proinflammatory enzymes such as inducible nitric oxide synthase (inoS) and cyclooxygenase 2 (CoX2) were As lipid chaperones, FABPs have been proposed to play a role in the transport of lipids to specific compartments in the cell: to lipid droplets for storage; to the endoplasmic reticulum for signalling, trafficking and membrane synthesis; to the mitochondria or peroxisome for oxidation; to cytosolic or other enzymes to regulate their activity; to the nucleus for the control of lipid-mediated transcriptional programs via nuclear hormone receptors (NHRs) or other transcription factors that respond to lipids; or even outside the cell to signal in an autocrine or paracrine manner. 
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Basal and stimulated lipolysis ↑; FA composition also suppressed 18 . It has also been demonstrated that A-FABP deficiency results in reduction in the activity of the inhibitor of kappa kinase (IKK)-nuclear factor-κB (nF-κB) pathway, which may, at least in part, underlie the alterations in cytokine expression 18 . Consequently, the overall reduction in foam-cell formation and modified inflammatory responses of A-FABP -/-macrophages was highly beneficial against the formation of atherosclerotic lesions in mouse models.
Brain FABP (B-FABP/FABP7)

B-FABP
A recent study showed that A-FABP was also expressed in human bronchial epithelial cells under highly specific conditions. The induction of A-FABP was only responsive to T helper 2 (T H 2) cytokines, IL4 and IL13, which are crucial to the development of asthma, whereas the T H 1 cytokine interferon-γ (IFn-γ) resulted in a moderate suppression of A-FABP 62 . It is worth noting that the level of A-FABP expression in bronchial epithelial cells was significantly lower when compared with adipocytes 
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and macrophages, even after stimulation. Interestingly, PPAR-γ agonists were unable to induce A-FABP expression in bronchial epithelial cells, and transcriptional regulation was mediated, at least in part, by signal transducer and activator of transcription 6 (STAT6) activity 62 . Interestingly, a striking protection from airway inflammation was detected in A-FABP-deficient mice, indicating possible protection against asthma 62 . In this setting, there was no detectable contribution of bone-marrow-derived elements in the airway phenotype associated with FABPdeficiency. Additionally, A-FABP expression was detected in lipoblasts in lipoblastoma and liposarcoma, but not in other benign adipose tissue or malignant connective tissue or epithelial tumours 64 . A-FABP expression has also been linked to human urothelial carcinomas 65 . The significance of these associations remains to be determined.
notably, recent studies conducted in our laboratory and by others showed that A-FABP was released from adipocytes and abundantly present in human serum. In addition, the concentration of A-FABP may be associated with obesity, type 2 diabetes and cardiovascular diseases [66] [67] [68] Epidermal FABP. e-FABP, also known as FABP5, psoriasis-associated FABP (PA-FABP) or mal1, is expressed most abundantly in epidermal cells of the skin. It is also present in other tissues, including the tongue, adipose tissue (adipocyte and macrophage), dendritic cell, mammary gland, brain, kidney, liver, lung and testis 6, 7, 60 . As all these tissues express additional members of the FABP family, the exact function of e-FABP is especially difficult to elucidate.
The ratio of A-FABP to e-FABP in adipocytes isolated from normal mice was approximately 99:1 (REF. 69 ). Although e-FABP is the minor fraction in adipocytes, the stochiometry of A-FABP and e-FABP appears to be approximately 1:1 in the macrophage under physiological conditions 55 . These two proteins have 52% amino-acid similarity and bind various fatty acids and synthetic compounds with similar selectivity and affinity 5 . Interestingly, e-FABP expression was dramatically increased in adipocytes, but not in macrophages, derived from A-FABP -/-mice 53, 55 . The mechanism underlying this striking molecular compensation is not known.
Transgenic mice overexpressing the e-FABP gene in adipose tissue exhibited a minor phenotype with enhanced basal and hormone-stimulated lipolysis 25 . when fed a high-fat diet, adipose tissue-specific e-FABP overexpression in transgenic mice resulted in a reduction in systemic insulin sensitivity 70 . By contrast, absence of e-FABP in these mice led to a modest increase in insulin sensitivity 70 . The adipocytes in E-FABP -/-mice showed an increased capacity for insulin-dependent glucose transport. other than increased H-FABP in liver 71 , no compensatory increase was observed in the expression of H-FABP, A-FABP or B-FABP in adipose tissue, testis, tongue or brain in E-FABP-deficient mice 70 .
Complete or partial lack of e-FABP in the liver during perinatal development was compensated by an overexpression of H-FABP 71 . otherwise, there were no apparent changes in morphology and histology in the liver of E-FABP -/-mice, and this model appeared remarkably healthy 71 . The loss of e-FABP in the epidermis did not alter the fatty-acid composition of the epidermal membrane, where fatty acids are essential components of the water permeability barrier of the skin 71 . There was only a minor reduction in transepidermal water loss in E-FABP-deficient mice as the water permeability barrier recovered more slowly following acetone-induced damage 71 . Interestingly, a study has shown that overexpression of e-FABP in a benign, non-metastatic rat mammary epithelial cell line may induce metastasis 72 . Hence, e-FABP seems to have the opposite effects to those reported for H-FABP (mDGI) and B-FABP (mRG), which inhibit tumour growth. e-FABP was also reported to influence survival pathways by activation of retinoic acid through PPAR-δ
73
. Taken together, there are interesting possibilities in linking FABP function to tumorigenesis, which remain largely unexplored. In addition, e-FABP is expressed in astrocytes and glia of the prenatal and perinatal brain, and, unlike B-FABP, also in neurons 74 . e-FABP expression was induced following peripheral nerve injury, suggesting a role in the regeneration of neurons 5 
.
Brain FABP. B-FABP, also known as FABP7, is expressed in various regions of the mouse brain in the mid-term embryonic stage, but the expression decreases as differentiation progresses 75 . The protein is strongly expressed in radial glia cells of the developing brain, especially in the preperinatal stage, but only weakly in mature glia of the white matter. neurons of the grey matter express H-FABP and e-FABP but not B-FABP. B-FABP is distinguished from other FABPs by its strong affinity for n-3 polyunsaturated fatty acids, in particular, docosahexaenoic acid. As this very long-chain fatty acid is an important nutrient for the nervous system, it has been considered a natural ligand for B-FABP 76 . Pathologically, B-FABP was overexpressed in patients with Down's syndrome 77 and schizophrenia 78 . Recently, B-FABP-deficient mice were shown to be viable with no macroscopic abnormalities 79 . Interestingly, B-FABPdeficient mice exhibited altered emotional behavioural responses, decreased prepulse inhibition that is a typical behaviour in schizophrenia, and attenuated neurogenesis in vivo 78, 79 . It has also been suggested that B-FABP influences the correct migration of developing neurons into cortical layers 75 . moreover, similar to H-FABP 42, 43 , B-FABP is prominently expressed in the mammary gland, and its overexpression inhibited tumour growth in a mouse breast cancer model 80, 81 . 
Toll-like receptors
Lipid chaperones and metabolic diseases As described above, adipocyte/macrophage FABPs, A-FABP and e-FABP, have a central role in many aspects of metabolic diseases including obesity, diabetes and atherosclerosis. The only cells that co-express A-FABP and e-FABP are adipocytes and macrophages. However, the dramatic compensation by e-FABP in adipocytes derived from A-FABP -/-mice had masked the effects of A-FABP-deficiency on overall metabolic health 53, 70 . To remove all FABP activity from these cells and address the metabolic impact of these FABP isoforms, mice with combined deficiency of A-FABP and e-FABP (A-FABP -/-
E-FABP
-/-) were also generated. The A-FABP -/-
-/-mice fed on a high-fat diet or in the context of severe genetic obesity exhibited alterations in tissue fatty-acid composition and did not develop insulin resistance, type 2 diabetes or fatty liver disease, demonstrating that the protective phenotype of this model far exceeds that of individual FABP-deficiency models 82, 83 . Similarly, when intercrossed into the ApoE -/-model, A-FABP
-/-mice developed dramatically less atherosclerosis compared with A-FABP-deficient or wild-type mice of the same background 84 .
ApoE
-/-animals also had significantly increased survival when fed a western-type hypercholesterolaemic diet, which is probably due to increased plaque stability and significant overall metabolic health 84 . It will be interesting to test whether this increase in survival could be extrapolated into increased longevity in this model.
A-FABP
-/-mice have one notable feature associated with obesity: a minor but significant elevation of plasma fatty acids 53, 54, 70, 82, 83 . In general, increased fatty acids are positively correlated with the development of obesity and insulin resistance, but paradoxically, adipocyte/macrophage FABP-deficient mouse models were more insulin sensitive. This observation challenges the current dogma in the mechanistic basis of fatty-acid action in the metabolic syndrome, and indicates that the distribution and availability of intracellular fatty acids (and derivatives), rather than the absolute amounts, may be more critical in pathological conditions. more detailed lipid profiling showed increased shorter-chain (C14) fatty acids and decreased longer-chain (C18 or C20) fatty acids in the muscle and adipose tissues of A-FABP -/-
E-FABP
-/-mice. These changes favoured enhanced insulin receptor signalling, insulin-stimulated glucose uptake, adenosine monophosphate-activated protein kinase (AmPK) activity, and fatty-acid oxidation 82 . There were also alterations in liver fatty-acid composition, which differed from other sites and favoured lipid mobilization over storage and suppressed stearoyl-coenzyme A desaturase (SCD) and sterol-regulatory element-binding protein (SReBP) activities, thus reducing hepatosteosis 82 . The A-FABP -/-
-/-mouse model has shed new light on the role of FABPs in regulating intracellular fatty-acid profiles and how these alterations are linked to specific biochemical pathways important in metabolic homeostasis.
It has recently been suggested that macrophage accumulation in adipose tissue is a feature of adipose tissue inflammatory responses triggered by obesity and hence may contribute to the metabolic consequences such as insulin resistance 85, 86 . Although the impact of A-FABP on atherosclerosis was essentially exclusive to its actions in the macrophage 55 , studies in cell-based experiments and bone-marrow transplantation using adipocyte/macrophage FABP-deficiency models showed that FABP action in both adipocytes and macrophages contribute to the inflammatory and metabolic responses . However, the impact of adipocyte FABP is again greater than the impact of bone-marrowderived cells on systemic insulin sensitivity and glucose metabolism in vivo 101 .
Therapeutic targeting of FABPs
Adipocyte/macrophage FABPs, A-FABP and e-FABP act at the interface of metabolic and inflammatory pathways. These FABPs exert a dramatic impact on obesity, insulin resistance, type 2 diabetes, fatty liver disease, atherosclerosis and asthma. The creation of pharmacological agents to modify FABP function may therefore provide tissue-specific or cell-type-specific control of lipid signalling pathways, inflammatory responses and metabolic regulation, thus offering a new class of multiindication therapeutic agents.
Recently, a small series of A-FABP inhibitors have been identified (TABLE 4) . These include carbazole-based (compounds 1 and 2) and indole-based (compounds 3a-c) inhibitors 87 ; benzylamino-6-(trifluoromethyl) pyrimidin-4(1H) inhibitors (compounds 4a-f) 88 ; and a biphenyl azole inhibitor (compound 5; also known as BmS309403) 89 . In a fluorescent 1-anilinonaphthalene-8-sulphonic acid binding displacement assay, BmS309403 had K i values <2 nm for A-FABP compared with 250 nm for H-FABP and 350 nm for e-FABP 89 . By contrast, the endogenous fatty acids, palmitic acid and oleic acid, had A-FABP K i values of 336 nm and 185 nm, respectively 89 . BmS309403 seems to have greater potency compared with the other reported potential inhibitors, which have IC 50 values >0.5 µm [87] [88] [89] .
In a recent study, we reported the development of an isoform-specific and biologically active synthetic A-FABP inhibitor, and demonstrated that chemical inhibition of A-FABP could be a potential therapeutic strategy against insulin resistance, diabetes, fatty liver disease as well as atherosclerosis in independent experimental models 90 . The orally active small-molecule BmS309403, a rationally designed, potent and selective inhibitor of A-FABP, interacts with the fatty-acid binding pocket within the interior of A-FABP to inhibit binding of endogenous fatty acids (FIG. 3) . Results of X-ray crystallography studies identified the specific interactions of BmS309403 with key residues, such as Ser53, Arg106, Arg126 and Tyr128, within the fatty-acid binding pocket as the basis of its high in vitro binding affinity and selectivity for A-FABP over other FABPs 89 . In particular, Ser53, which is a Thr in H-FABP and e-FABP, is proximal to the ethyl substituent of the pyrazole ring and might act as a critical residue to influence ligand interactions.
BmS309403 markedly reduced the extent of atherosclerotic lesions in ApoE -/-mice 90 . Cell-based studies revealed reduced macrophage foam-cell formation with decreased cholesterol-ester accumulation, increased cholesterol efflux and decreased production of several inflammatory mediators by this inhibitor in a targetspecific manner. BmS309403 did not produce these effects in cells lacking A-FABP. Inhibition of A-FABP improved glucose metabolism and enhanced insulin sensitivity in both dietary and genetic mouse models of obesity and diabetes 90 . Furthermore, fatty liver infiltration and the expression of obesity-associated inflammatory mediators were also suppressed in the insulin resistant and obese ob/ob mouse model. The activity of JnK1, which is crucial in the generation of inflammatory responses and inhibition of insulin action in obesity 91, 92 , was also attenuated together with improved insulin action in both adipose and liver tissues upon A-FABP inhibition 90 . Previous studies suggest that the expression, regulation and metabolic function of human A-FABP may be similar to that of mice 5, 53, 55 . In fact, a genetic variant was identified within the promoter region of the human A-FABP gene (T-87C), which altered C/eBP binding and significantly reduced the transcriptional activity of the human A-FABP promoter, resulting in diminished A-FABP expression in adipose tissue of carriers with this allele 93 . In a large population sampling, individuals with the A-FABP variant had lower triglyceride levels, had reduced cardiovascular disease risk, and were protected from obesity-induced type 2 diabetes 93 . This study provided a critical proof of principle that the biological functions of A-FABP may be similar between mice and humans. Definitive genetic links will require additional large-scale population studies to determine whether this applies to different cohorts. Further studies are also needed to determine whether FABP inhibitors could be safely used in humans and show efficacy against metabolic diseases. If successful, inhibition of A-FABP in humans may become a promising new class of therapeutics against a broad range of metabolic diseases including obesity, insulin resistance, type 2 diabetes, atherosclerosis and possibly other inflammatory conditions such as asthma. Concluding remarks FABP-mediated lipid metabolism is closely linked to both metabolic and inflammatory processes through modulating critical lipid-sensitive pathways in target cells, especially adipocytes and macrophages. mice under normal physiological conditions did not have a compromised phenotype when adipocyte/macrophage FABPs were deleted, but they benefited enormously when faced with systemic pathological stresses, particularly of metabolic and inflammatory origin. The phenotypes observed in the absence of adipocyte/macrophage FABPs illustrate the integrating role in metabolic and inflammatory responses, and suggest that these genes may represent an example of the "thrifty" gene hypothesis 94 . evolutionary selection has clearly preserved the function of FABPs in that they are present in invertebrates (lower eukaryotes) up to vertebrates, including humans 95 . It may be that the close link between the inflammatory and metabolic responses underlie this conservation. The adipocyte/ macrophage FABPs may be necessary to fine-tune the balance between the availability of metabolic resources and the control of inflammatory responses. That is, when humans faced feast or famine and when under pressure with pathogens, the presence of FABPs may have been beneficial by ensuring a strong macrophage immune response or by maintaining adipose tissue energy stores as part of the "thrifty" phenotype to survive. under the unnaturally excessive and continuous caloric intake, decreased energy expenditure, prolonged lifespan and the distinctly stressful lifestyle of contemporary humans, FABPs may not be sufficient to maintain inflammatory or metabolic homeostasis, and hence no longer be beneficial. In this scenario, their presence now facilitates the formation of obesity, diabetes, dyslipidaemia, atherosclerosis and inappropriate immune responses. In such conditions, targeting the adipocyte/ macrophage FABPs, particularly A-FABP, offers highly attractive therapeutic opportunities for a broad range of pathologies in metabolic diseases by addressing an evolutionary bottleneck in the metabolic design of humans. In addition to the well-studied and characterized isoforms, FABPs in general may also offer targeting opportunities for the development of therapeutic or preventive agents for other diseases. For example, H-FABP and B-FABP may be targeted in tumours where they are heavily and aberrantly expressed, and regulate growth and survival responses. much work is still needed in mouse models to illustrate the precise applications and indications for other isoforms. moreover, as well as targeting these molecules directly, the ability of FABPs to modulate lipid signalling and trafficking in a tissue-specific or restricted manner could also be exploited for controlling the activity of their targets such as nuclear hormone receptors in select cell types and tissues. Development of high affinity and selective chemicals to target A-FABP provides a critical proof of principle that this class of proteins are suitable for drug development. Future studies should also increase the repertoire of synthetic ligands for the additional members of the FABP family as their biological functions become better understood.
